Journal ArticleDOI
Cardiac Resynchronization in Chronic Heart Failure
William T. Abraham,Westby G. Fisher,Andrew L. Smith,David B. Delurgio,Angel R. Leon,Evan Loh,Dusan Z. Kocovic,Milton Packer,Alfredo L. Clavell,David L. Hayes,Myrvin H. Ellestad,Robin J. Trupp,Jackie Underwood,Faith Pickering,Cindy Truex,Peggy McAtee,John C. Messenger +16 more
Reads0
Chats0
TLDR
Cardiac resynchronization results in significant clinical improvement in patients who have moderate-to-severe heart failure and an intraventricular conduction delay.Abstract:
Background Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach. Methods Four hundred fifty-three patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec or more were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control group (225 patients) for six months, while conventional therapy for heart failure was maintained. The primary end points were the New York Heart Association functional class, quality of life, and the distance walked in six minutes. Results As compared with the control group, patients assigned to cardiac resynchronization experienced an improvement in the distance walked in six minutes (+39 vs. +10 m, P=0.005), functional clas...read more
Citations
More filters
Journal ArticleDOI
Effect of biventricular pacing on the exercise pathophysiology of heart failure.
TL;DR: BVP benefited aerobic function and ventilation-perfusion mismatching most in those patients with the greatest physiologic impairment.
Journal ArticleDOI
Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial.
David O. Martin,John D. Day,Peter Y Lai,Allan Murphy,Hemal M. Nayak,Rollo P Villareal,Stanislav Weiner,Stacia Merkel Kraus,Kira Q. Stolen,Michael R. Gold +9 more
TL;DR: The PEGASUS CRT trial as mentioned in this paper evaluated the effect of atrial support pacing among heart failure patients receiving a CRT defibrillator, and showed that atrial pacing did not adversely affect mortality or heart failure events.
Journal ArticleDOI
Impact of the right ventricular lead position on clinical outcome and on the incidence of ventricular tachyarrhythmias in patients with CRT-D
Valentina Kutyifa,Valentina Kutyifa,Poul Erik Bloch Thomsen,David T. Huang,Spencer Rosero,Christine Tompkins,Christian Jons,Scott McNitt,Bronislava Polonsky,Amil M. Shah,Bela Merkely,Scott D. Solomon,Arthur J. Moss,Wojciech Zareba,Helmut U. Klein +14 more
TL;DR: Nonapical RV lead location is associated with an increased risk of ventricular tachyarrhythmias, particularly in the first year after device implantation, and results were consistent in patients with left bundle branch block.
Journal ArticleDOI
Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial—Cardiac Resynchronization Therapy (MADIT-CRT)
Ilan Goldenberg,Arthur J. Moss,Scott McNitt,Alon Barsheshet,Daniel A. Gray,Mark L. Andrews,Mary W. Brown,Wojciech Zareba,Edward Sze,Scott D. Solomon,Marc A. Pfeffer +10 more
TL;DR: In MADIT-CRT, patients with an elevated ratio of BUN to SCr experienced a significantly greater reduction in the risk of HF or death with CRT-D therapy as compared with patients with a low ratio.
Journal ArticleDOI
Long-term effects of upgrading to biventricular pacing: differences with cardiac resynchronization therapy as primary indication.
Gaetano Paparella,Luigi Sciarra,Lucio Capulzini,Anna Francesconi,Carlo De Asmundis,Andrea Sarkozy,Roberto Cazzin,Pedro Brugada +7 more
TL;DR: The long‐term effects of cardiac resynchronization therapy (CRT) in patients with advanced heart failure and previously right ventricular apical pacing are studied.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
Serge Cazeau,Christophe Leclercq,Thomas Lavergne,S Walker,Varma C,Cecilia Linde,Stéphane Garrigue,Lukas Kappenberger,G A Haywood,Massimo Santini,Bailleul C,Jean-Claude Daubert,Multisite Stimulation in Cardiomyopathies (Mustic) Study Investigators +12 more
TL;DR: In this article, transvenous atriobiventricular pacemakers (with leads in one atrium and each ventricle) were used to reduce ventricular asynchrony.
Journal Article
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure
Gordon H. Guyatt,Michael J. Sullivan,Penelope J. Thompson,Ernest L. Fallen,S. O. Pugsley,D W Taylor,Leslie B. Berman +6 more
TL;DR: It is concluded that the 6-minute walk is a useful measure of functional exercise capacity and a suitable measure of outcome for clinical trials in patients with chronic heart failure.
Journal ArticleDOI
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
Bertram Pitt,Philip A. Poole-Wilson,Robert Segal,Felipe Martinez,Kenneth Dickstein,A. John Camm,Marvin A. Konstam,Günter A.J. Riegger,George Klinger,James D. Neaton,Divakar Sharma,Balasamy Thiyagarajan +11 more
TL;DR: The ELITE II Losartan Heart Failure Survival Study as discussed by the authors showed an association between the angiotensin II antagonist losartan and an unexpected survival benefit in elderly heart-failure patients, compared with captopril, an ACE inhibitor.